NLNK NewLink Genetics Corporation

+0.02  (+1%)
Previous Close 1.54
Open 1.54
Price To Book 0.54
Market Cap 58,150,719
Shares 37,276,102
Volume 335,980
Short Ratio
Av. Daily Volume 328,447

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data presented at ASCO June 4, 2017. Abstract 105.
GDC-0919 and atezolizumab
Solid tumors
Phase 2 poster presentation at ASCO June 5, 2017.
Indoximod + Sipuleucel-T
Metastatic castration resistant prostate cancer (mCRPC)
Phase randomization portion will not be initiated - noted April 15, 2018.
Indoximod in combination with KEYTRUDA or Opdivo - Indigo301
Melanoma - cancer
Phase 2 data presented at ASCO 2018. Primary endpoint not met.
Indoximod + gemcitabine and nab-paclitaxel
Pancreatic cancer
Phase 3 failed to meet primary endpoint - May 2016
HyperAcute Pancreas - IMPRESS
Surgically resected pancreatic cancer
Phase 3 failed to show improvement in survival.
HyperAcute Pancreas - PILLAR
Pancreatic cancer
Phase 2 trial did not meet endpoints - noted June 2, 2017.
Indoximod + taxane
Cancer - breast
Phase 1b data to be presented at ASH December 2018.
Indoximod plus standard-of-care chemotherapy
Acute myeloid leukemia (AML)
Phase 1 updated data due 2019.
Indoximod in combination with chemotherapy and radiation
Diffuse intrinsic pontine glioma (DIPG)
Phase 1 updated data presented May 23, 2019.
Solid tumors
Rolling BLA filing has commenced - noted November 13, 2018.
Phase 2 data presented at AACR April 2, 2019. ORR 27%.
NLG207 (CRLX101) and paclitaxel
Platinum-resistant ovarian cancer

Latest News

  1. Implied Volatility Surging for NewLink Genetics (NLNK) Stock Options
  2. Celgene (CELG) Hits 52-Week High, Can the Run Continue?
  3. NewLink Genetics Presents Updated NLG802 Results at the Immuno-Oncology 2019 World Congress
  4. Edited Transcript of NLNK earnings conference call or presentation 8-May-19 8:30pm GMT
  5. NewLink: 1Q Earnings Snapshot
  6. NewLink Genetics Reports First Quarter 2019 Financial Results and Provides Clinical Activities Update
  7. NewLink Genetics to Participate in Upcoming Investor and Medical Conferences
  8. NewLink Genetics Corporation (NASDAQ:NLNK): Earnings Expected To Remain Subdued
  9. NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019
  10. NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
  11. The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
  12. 4 Small Biotech Stocks Likely to Witness More Upside in 2019
  13. Edited Transcript of NLNK earnings conference call or presentation 27-Feb-19 9:30pm GMT
  14. Do Institutions Own Shares In NewLink Genetics Corporation (NASDAQ:NLNK)?
  15. NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
  16. NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
  17. NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
  18. Factors of Influence in 2019, Key Indicators and Opportunity within Marathon Oil, Accuray, United Natural Foods, Systemax, Amgen, and NewLink Genetics — New Research Emphasizes Economic Growth
  19. NewLink Genetics to Participate in the Immuno-Oncology 360° Conference
  20. Before You Buy NewLink Genetics Corporation (NASDAQ:NLNK), Consider Its Volatility